Few are the people who have set out to work towards something and have ultimately lived their dream. Clay Siegall is one of the few. He has co-founded, Seattle Genetics, the reputable cancer research firm. More so, he holds the company’s helm as the President, Chief Executive Officer and the Chairman of the Board. He has received training as a scientist focusing on targeted cancer treatments. His company is among the leading healthcare research institutions focusing on the formulation of cancer drugs. The institution is built on a solid base of scientific innovation, in-depth research, drug development practices and above all the passion for helping patients.
Under his informed leadership, the company has reached several core milestones in its operations. For starters, the company is leading in the development of Antibody-drug Conjugates (ADC). Moreover, it secured the FDA approval (2011) for its first ADC product. The drug is currently a global brand used in more than 65 countries in the world. Besides, the institution is focused on the advancement of an extensive pipeline of exclusive ADCs for cancer treatment. Again, the firm has joined forces through multiple strategic alliances with different organizations to advance its distinct ADC technology. To the present, these collaborations have generated the firm well over 350 million dollars. On record, more than 20 cancer treatment products utilize the company’s technology that has seen its capital steadily rising to a tune of .2 billion dollars.
Clay Siegall has spanned a highly successful career in the health sector. Prior to Seattle Genetics, he had worked with Bristol-Myers Squibb Pharmaceutical Research Institute. Also, he had served with the National Cancer Institute and National Institutes of Health. Besides, he has rendered directorial services to Alder BioPharmaceuticals, Washington Roundtable, and Ultragenyx Pharmaceutical, a bio-pharmaceutical company focused on developing novel products for rare and ultra-rare diseases. He also serves as a Director on the Board of Mirna Therapeutics, an organization aimed at developing and commercializing microRNA therapeutics.
Clay Siegall’s achievements have been significant. As a result of his dedication to his work and desire to help, he has received numerous recognition and awards including the 2012 Pacific Northwest Ernst &Young Entrepreneur of the Year and also the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. He has been a success and has lived his dream to see cancer patients benefit from his efforts.